Iyoda, Shinju
Yoshida, Kenichi http://orcid.org/0000-0003-4612-2778
Shoji, Kota
Ito, Nana
Tanaka, Miu
Nannya, Yasuhito
Yamato, Genki http://orcid.org/0000-0003-4000-0753
Tsujimoto, Shinichi http://orcid.org/0000-0001-5738-4138
Shiba, Norio
Hayashi, Yasuhide
Shiozawa, Yusuke
Shiraishi, Yuichi
Chiba, Kenichi
Okada, Ai
Tanaka, Hiroko
Miyano, Satoru http://orcid.org/0000-0002-1753-6616
Koga, Yuhki
Goto, Hiroaki
Moritake, Hiroshi http://orcid.org/0000-0001-5471-7646
Terui, Kiminori http://orcid.org/0000-0003-1294-8635
Ito, Etsuro http://orcid.org/0000-0002-0168-2475
Kiyokawa, Nobutaka http://orcid.org/0000-0001-9310-2126
Tomizawa, Daisuke http://orcid.org/0000-0003-1520-7007
Taga, Takashi http://orcid.org/0000-0003-0525-4766
Tawa, Akio
Takita, Junko http://orcid.org/0000-0002-2452-6520
Nishikori, Momoko
Adachi, Souichi
Ogawa, Seishi
Matsuo, Hidemasa http://orcid.org/0000-0002-7578-006X
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP19K16832, JP22K08475, JP23K07264)
Japan Agency for Medical Research and Development (Practical Research for Innovative Cancer Control, Project for Development of Innovative Research on Cancer Therapeutics, Project for Cancer Research and Therapeutic Evolution)
Article History
Received: 19 March 2024
Revised: 31 March 2024
Accepted: 3 April 2024
First Online: 18 April 2024
Competing interests
: SO: Leadership position/advisory role for Eisai, Chordia Therapeutics. Stockholder in: Asahi Genomics. Grant/Research funding from Chordia Therapeutics, Otsuka Pharmaceutical, Eisai. The remaining authors declare no competing financial interests.